Citations

Clear

3942 citation(s) found for "To, Van".

V̇o2 kinetics associated with moderate-intensity exercise in heart failure: impact of intrathecal fentanyl inhibition of group III/IV locomotor muscle afferents
Iterson, Erik H. Van , Johnson, Bruce D. , Joyner, Michael J. , Curry, Timothy B. , Olson, Thomas P. , Van Iterson, Erik H , Joyner, Michael J

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | May 5, 2017 | Volume: 313 | Issue: 1 | Pages: H114-H124

10.1152/ajpheart.00014.2017 | PMID 28476919 Get It

Heart failure (HF) patients demonstrate impaired pulmonary, circulatory, and nervous system responses to exercise. While HF demonstrates prolonged [time constant (τ)] pulmonary O2 uptake (V̇o2) on-kinetics, contributing to exercise intolerance, it is unknown whether abnormal V̇o2 kinetics couple with ventilatory and circulatory dysfunction secondary to impaired group III/IV afferents in HF. Because lower lumbar intrathecal fentanyl inhibits locomotor muscle afferents, resulting in improved exercise ventilation and hemodynamics, we tested these hypotheses: HF will demonstrate 1) rapid V̇o2 on-kinetics and 2) attenuated steady-state V̇o2 amplitude and O2 deficit (O2def) during exercise with fentanyl versus placebo. On separate visits (randomized), breath-by-breath V̇o2 was measured in HF (ejection fraction: 27 ± 6%, New York Heart Association class I–III) and age- and sex-matched controls (both n = 9, ages: 60 ± 6 vs. 63 ± 8 yr, P = 0.37) during cycling transitions at 65% peak workload (78 ± 24 vs. 115 ± 39 W, P < 0.01) with intrathecal fentanyl or placebo. Regardless of group or condition, optimal phase II (primary component) curve fits reflected a phase I period equal to 35 s (limb-to-lung timing) via single-exponential functions. Condition did not affect steady-state V̇o2, the phase II τ of V̇o2, or O2def within controls ( P > 0.05). Without differences in steady-state V̇o2, reduced O2def in fentanyl versus placebo within HF (13 ± 4 vs. 22 ± 15 ml/W, P = 0.04) was accounted for by a rapid phase II τ of V̇o2 in fentanyl versus placebo within HF (45 ± 11 vs. 57 ± 14 s, P = 0.04), respectively. In an integrative manner, these data demonstrate important effects of abnormal locomotor muscle afferents coupled to pulmonary and circulatory dysfunction in determining impaired exercise V̇o2 in HF. Effects of abnormal muscle afferents on impaired exercise V̇o2 and hence exercise intolerance may not be discernable by independently assessing steady-state V̇o2 in HF. NEW & NOTEWORTHY Inhibition of locomotor muscle afferents results in rapid primary-component O2 uptake (V̇o2) on-kinetics accounting for the decreased O2 deficit in heart failure (HF). This study revealed that abnormal musculoskeletal–neural afferents couple with pulmonary and circulatory dysfunction to provoke impaired exercise V̇o2 in HF. Steady-state V̇o2 cannot properly phenotype abnormal muscle afferent contributions to impaired exercise V̇o2 in HF.
Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance
Ho, Yeung, Etten, Jamie L. Van, Yang, Rendong , Li, Yingming , Tseng, Elizabeth , Hon, Ting, Clark, Tyson A. , Tan, Winston , Carlson, Rachel E. , Wang, Liguo , Sicotte, Hugues , Ho, Thai H. , Jiménez, Rafael E. , Vedell, Peter T. , Eckloff, Bruce W., Quevedo, J. Fernando , Pitot, Henry C., Costello, Brian A. , Jen, Jin , Wieben, Eric D. , Silverstein, Kevin A.T. , Wang, Liewei , Dehm, Scott M. , Kohli, Manish , Thai, Ho, Jimenez, Rafael, Quevedo, Jorge F, Hillman, David W. , Henzler, Christine M. , Sperger, Jamie M. , Huang, Haojie , Lang, Joshua M. , Ho, Thai , Wang, Liguo , Dehm, Scott M

Mayo Clinic

Clinical Cancer Research | May 4, 2017 | Volume: 23 | Issue: 16 | Pages: 4704-4715

10.1158/1078-0432.ccr-17-0017 | PMID 28473535 Get It

Abstract Purpose: Androgen receptor (AR) variant AR-V7 is a ligand-independent transcription factor that promotes prostate cancer resistance to AR-targeted therapies. Accordingly, efforts are under way to develop strategies for monitoring and inhibiting AR-V7 in castration-resistant prostate cancer (CRPC). The purpose of this study was to understand whether other AR variants may be coexpressed with AR-V7 and promote resistance to AR-targeted therapies. Experimental Design: We utilized complementary short- and long-read sequencing of intact AR mRNA isoforms to characterize AR expression in CRPC models. Coexpression of AR-V7 and AR-V9 mRNA in CRPC metastases and circulating tumor cells was assessed by RNA-seq and RT-PCR, respectively. Expression of AR-V9 protein in CRPC models was evaluated with polyclonal antisera. Multivariate analysis was performed to test whether AR variant mRNA expression in metastatic tissues was associated with a 12-week progression-free survival endpoint in a prospective clinical trial of 78 CRPC-stage patients initiating therapy with the androgen synthesis inhibitor, abiraterone acetate. Results: AR-V9 was frequently coexpressed with AR-V7. Both AR variant species were found to share a common 3′ terminal cryptic exon, which rendered AR-V9 susceptible to experimental manipulations that were previously thought to target AR-V7 uniquely. AR-V9 promoted ligand-independent growth of prostate cancer cells. High AR-V9 mRNA expression in CRPC metastases was predictive of primary resistance to abiraterone acetate (HR = 4.0; 95% confidence interval, 1.31–12.2; P = 0.02). Conclusions: AR-V9 may be an important component of therapeutic resistance in CRPC. Clin Cancer Res; 23(16); 4704–15. ©2017 AACR.
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Höglinger, Günter U. , Respondek, Gesine , Stamelou, María , Kurz, Carolin , Josephs, Keith A. , Lang, Anthony E. , Mollenhauer, Brit , Müller, Ulrich , Whitwell, Jennifer L. , Arzberger, Thomas, Englund, Elisabet , Gelpí, Ellen , Irwin, David J. , Meissner, Wassilios G. , Pantelyat, Alexander , Rajput, Alex, Swieten, John C. van, Troakes, Claire , Antonini, Angelo , Bordelon, Yvette , Compta, Yaroslau , Corvol, Jean‐Christophe , Dodel, Richard , Ferguson, Leslie W. , Kassubek, Jan , Krismer, Florian , Xiong, Chengjie , Lorenzl, Stefan , Morris, Huw R. , Nestor, Peter J. , Oertel, Wolfgang H., Rabinovici, Gil D. , Rowe, James B. , Schellenberg, Gerard D., Seppi, Klaus , Eimeren, Thilo van , Wenning, Gregor K. , Boxer, Adam L. , Golbe, Lawrence I. , Group, for the Movement Disorder Society–endorsed PSP Study, Meissner, Wassilios G , Bhatia, Kailash P , Nilsson, Christer C. , Giese, Armin , Swieten, John C. van , Bhatia, Kailash P. , Colosimo, Carlo , Dickson, Dennis W. , Grossman, Murray , Krismer, Florian , Poewe, Werner H , Schellenberg, Gerard D., Litvan, Irene , Group, for the Movement Disorder Society–endorsed PSP Study, Höglinger, Günter U , Lang, Anthony E , Irwin, David J , Antonini, Angelo , Rowe, James B , Corvol, Jean-Christophe , Seppi, Klaus , Xiong, Chengjie , Gelpi, Ellen , Pantelyat, Alex , Rabinovici, Gil D , Troakes, Claire , Morris, Huw R , van Eimeren, Thilo

Mayo Clinic

Movement Disorders | May 3, 2017 | Volume: 32 | Issue: 6 | Pages: 853-864

10.1002/mds.26987 | PMID 28467028 Get It

ABSTRACT Background : PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria, published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for PSP, have excellent specificity, but their sensitivity is limited for variant PSP syndromes with presentations other than Richardson's syndrome. Objective : We aimed to provide an evidence‐ and consensus‐based revision of the clinical diagnostic criteria for PSP. Methods : We searched the PubMed, Cochrane, Medline, and PSYCInfo databases for articles published in English since 1996, using postmortem diagnosis or highly specific clinical criteria as the diagnostic standard. Second, we generated retrospective standardized clinical data from patients with autopsy‐confirmed PSP and control diseases. On this basis, diagnostic criteria were drafted, optimized in two modified Delphi evaluations, submitted to structured discussions with consensus procedures during a 2‐day meeting, and refined in three further Delphi rounds. Results : Defined clinical, imaging, laboratory, and genetic findings serve as mandatory basic features, mandatory exclusion criteria, or context‐dependent exclusion criteria. We identified four functional domains (ocular motor dysfunction, postural instability, akinesia, and cognitive dysfunction) as clinical predictors of PSP. Within each of these domains, we propose three clinical features that contribute different levels of diagnostic certainty. Specific combinations of these features define the diagnostic criteria, stratified by three degrees of diagnostic certainty (probable PSP, possible PSP, and suggestive of PSP). Clinical clues and imaging findings represent supportive features. Conclusions : Here, we present new criteria aimed to optimize early, sensitive, and specific clinical diagnosis of PSP on the basis of currently available evidence. © 2017 International Parkinson and Movement Disorder Society
Detecting fasciculations in cranial nerve innervated muscles with ultrasound in amyotrophic lateral sclerosis
O’Gorman, Cullen , Weikamp, Janneke G. , Baria, Michael R. , Engel–Hoek, L. van den , Kassardjian, Charles D. , Boon, Andrea J. , O'gorman, Cullen M , Van Den Engel-Hoek, Lenie , Kassardjian, Charles, Alfen, Nens van

Mayo Clinic

Muscle & Nerve | April 30, 2017 | Volume: 56 | Issue: 6 | Pages: 1072-1076

10.1002/mus.25676 | PMID 28457000 Get It

ABSTRACTIntroductionCranial muscle fasciculations may be difficult to detect in amyotrophic lateral sclerosis (ALS). Ultrasound (US) detection of fasciculations in these muscles may have clinical utility.MethodsPatients with suspected ALS were prospectively enrolled. Nerve conduction studies, needle electromyography (EMG), and US examination of cranial muscles were performed. Controls were examined by US only. Fasciculations were counted and scored for each muscle after 10 or 30 seconds.ResultsThere were 84 patients with ALS. Fasciculations were most frequently found in the genioglossus muscle. Overall, detection rates by US and EMG were similar, but US was more likely to detect frequent fasciculations. Fasciculations were rare in controls, seen in 7 of 1,090 (0.6%) muscles. No control had > 5 fasciculations in any muscle.DiscussionFasciculations were frequently detected in cranial muscles of patients with ALS. US was found to be a sensitive method, and was not impaired by factors such as anxiety and the inability of the patient to relax. Muscle Nerve 56: 1072–1076, 2017
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
LaPlant, Betsy, Call, Timothy G. , Leis, José F., He, Rong , Wiseman, Gregory A., Lin, Yi , Asmus, Erik, Nowakowski, Grzegorz S. , Conte, Michael, Bowen, Deborah A., Aitken, Casey N., Dyke, Daniel L. Van , Greipp, Patricia T. , Wu, Xiaosheng , Secreto, Charla, Tian, Shulan , Braggio, Esteban , Wellik, Linda, Micallef, Ivana N. , Viswanatha, David S., Yan, Huihuang , Chanan‐Khan, Asher , Ansell, Stephen M. , LaPlant, Betsy R, Chanan-Khan, Asher A., Ding, Wei , Parikh, Sameer A. , Shanafelt, Tait D. , Sinha, Sutapa , Le‐Rademacher, Jennifer , Feldman, Andrew L. , Habermann, Thomas M. , Witzig, Thomas E. , Liu, Xin , Zhang, Henan , Kay, Neil E. , Dong, Haidong , Braggio, Esteban , Greipp, Patricia T , Lin, Yi

Mayo Clinic

Blood | April 20, 2017 | Volume: 129 | Issue: 26 | Pages: 3419-3427

10.1182/blood-2017-02-765685 | PMID 28424162 Get It

Key Points Pembrolizumab was first shown to be clinically active in CLL patients with RT. PD-1 and PD-L1 expression in tumor microenvironment are promising biomarkers to select RT patients for PD-1 blockade.
Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database
Renfro, Lindsay A. , Goldberg, Richard M. , Sobrero, Alberto , Adams, Richard , Seymour, Michel , Heinemann, Volker , Schmoll, Hans‐Joachim , Douillard, Jean‐Yves , Hurwitz, Herbert I. , Fuchs, Charles S. , Díaz‐Rubio, Eduardo , Porschen, Rainer, Tournigand, Christophe , Chibaudel, Benoist , Hoff, Paulo M. , Kabbinavar, Fairooz F. , Falcone, Alfredo , Punt, Cornelis J.A. , Hecht, J. Randolph, Souglakos, John , Bokemeyer, Carsten , Gramont, Aimery de , Seymour, Matthew T, Hurwitz, Herbert, Díaz-Rubio, Eduardo, Tebbutt, Niall C. , van Cutsem, Eric, Saltz, Leonard, de Gramont, Aimery, Grothey, Axel , Cutsem, Eric Van , Saltz, Leonard B. , Sargent, Daniel J. , Falcone, Alfredo , Seymour, Matthew T , Adams, Richard , Schmoll, Hans-Joachim , Chibaudel, Benoist

Mayo Clinic

Journal of Clinical Oncology | April 17, 2017 | Volume: 35 | Issue: 17 | Pages: 1929-1937

10.1200/jco.2016.71.5771 | PMID 28414610 Get It

Purpose Factors contributing to early mortality after initiation of treatment of metastatic colorectal cancer are poorly understood. Materials and Methods Data from 22,654 patients enrolled in 28 randomized phase III trials contained in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were pooled. Multivariable logistic regression models for 30-, 60-, and 90-day mortality were constructed, including clinically and statistically significant patient and disease factors and interaction terms. A calculator (nomogram) for 90-day mortality was developed and validated internally using bootstrapping methods and externally using a 10% random holdout sample from each trial. The impact of early progression on the likelihood of survival to 90 days was examined with time-dependent Cox proportional hazards models. Results Mortality rates were 1.4% at 30 days, 3.4% at 60 days, and 5.5% at 90 days. Among baseline factors, advanced age, lower body mass index, poorer performance status, increased number of metastatic sites, BRAF mutant status, and several laboratory parameters were associated with increased likelihood of early mortality. A multivariable model for 90-day mortality showed strong internal discrimination (C-index, 0.77) and good calibration across risk groups as well as accurate predictions in the external validation set, both overall and within patient subgroups. Conclusion A validated clinical nomogram has been developed to quantify the risk of early death for individual patients during initial treatment of metastatic colorectal cancer. This tool may be used for patient eligibility assessment or risk stratification in future clinical trials and to identify patients requiring more or less aggressive therapy and additional supportive measures during and after treatment.
Brain‐responsive neurostimulation in patients with medically intractable mesial temporal lobe epilepsy
Geller, Eric B., Skarpaas, Tara L. , Barkley, Gregory L., Bazil, Carl W., Berg, Michael J. van den, Bergey, Gregory K. , Cash, Sydney S. , Cole, Andrew J. , Duckrow, Robert B., Eisenschenk, Stephan, Fessler, James, Fountain, Nathan B. , Goldman, Alicia, Gwinn, Ryder P. , Heck, Christianne, Herekar, Aamar, Hirsch, Lawrence J. , Jobst, Barbara C. , King‐Stephens, David , Labar, Douglas, Leiphart, James W., Marsh, W. Richard , Meador, Kimford J. , Mizrahi, Eli M., Murro, Anthony M., Nair, Dileep , Park, Yong D., Rutecki, Paul , Salanova, Vicenta , Sheth, Raj D. , Shields, Donald C. , Skidmore, Christopher , Spencer, David , Srinivasan, Shraddha, Tatum, William O. , Ness, Paul C. Van, Vossler, David G. , Wharen, Robert E. , Yoshor, Daniel , Zimmerman, Richard S. , Cicora, Kathy, Sun, Felice T., Morrell, Martha J. , Cole, Andrew J , Noe, Katherine H. , Gross, Robert E. , Goodman, Robert , Berg, Michael J., Edwards, Jonathan , Smith, Michael C. F. , Worrell, Gregory A. , Fountain, Nathan , Hirsch, Lawrence J , Meador, Kimford J , Jobst, Barbara , Nair, Dileep R , Skidmore, Christopher , Morrell, Martha J

Mayo Clinic

Epilepsia | April 11, 2017 | Volume: 58 | Issue: 6 | Pages: 994-1004

10.1111/epi.13740 | PMID 28398014 Get It

SummaryObjectiveEvaluate the seizure‐reduction response and safety of mesial temporal lobe (MTL) brain‐responsive stimulation in adults with medically intractable partial‐onset seizures of mesial temporal lobe origin.MethodsSubjects with mesial temporal lobe epilepsy (MTLE) were identified from prospective clinical trials of a brain‐responsive neurostimulator (RNS System, NeuroPace). The seizure reduction over years 2–6 postimplantation was calculated by assessing the seizure frequency compared to a preimplantation baseline. Safety was assessed based on reported adverse events.ResultsThere were 111 subjects with MTLE; 72% of subjects had bilateral MTL onsets and 28% had unilateral onsets. Subjects had one to four leads placed; only two leads could be connected to the device. Seventy‐six subjects had depth leads only, 29 had both depth and strip leads, and 6 had only strip leads. The mean follow‐up was 6.1 ± (standard deviation) 2.2 years. The median percent seizure reduction was 70% (last observation carried forward). Twenty‐nine percent of subjects experienced at least one seizure‐free period of 6 months or longer, and 15% experienced at least one seizure‐free period of 1 year or longer. There was no difference in seizure reduction in subjects with and without mesial temporal sclerosis (MTS), bilateral MTL onsets, prior resection, prior intracranial monitoring, and prior vagus nerve stimulation. In addition, seizure reduction was not dependent on the location of depth leads relative to the hippocampus. The most frequent serious device‐related adverse event was soft tissue implant‐site infection (overall rate, including events categorized as device‐related, uncertain, or not device‐related: 0.03 per implant year, which is not greater than with other neurostimulation devices).SignificanceBrain‐responsive stimulation represents a safe and effective treatment option for patients with medically intractable epilepsy, including patients with unilateral or bilateral MTLE who are not candidates for temporal lobectomy or who have failed a prior MTL resection.
Adjunctive Corticosteroid Therapy in the Treatment of Coccidioidal Meningitis
Blair, Janis E. , Wang, Sharon, Bercovitch, Robert, Bolaris, Michael , Akker, Dane Van Den, Heidari, Arash , Catanzaro, Antonino , Chin‐Hong, Peter , Spellberg, Brad , Johnson, Royce H. , Thompson, George R , López, Rodrigo , Cadena, José

Mayo Clinic

Clinical Infectious Diseases | April 10, 2017 | Volume: 65 | Issue: 2 | Pages: 338-341

10.1093/cid/cix318 | PMID 28419259 Get It

Brain‐responsive neurostimulation in patients with medically intractable seizures arising from eloquent and other neocortical areas
Jobst, Barbara C. , Kapur, Ritu, Barkley, Gregory L., Bazil, Carl W., Berg, Michel J., Bergey, Gregory K. , Boggs, Jane , Cash, Sydney S. , Cole, Andrew J. , Duchowny, Michael , Duckrow, Robert B., Eisenschenk, Stephan, Fessler, A. James, Fountain, Nathan B. , Geller, Eric B., Gwinn, Ryder P. , Heck, Christianne, Herekar, Aamr A., Hirsch, Lawrence J. , King‐Stephens, David , Labar, Douglas, Marsh, W. Richard , Meador, Kimford J. , Miller, Ian , Mizrahi, Eli M., Murro, Anthony M., Nair, Dileep , Olejniczak, Piotr W., Park, Yong D., Rutecki, Paul , Salanova, Vicenta , Sheth, Raj D. , Skidmore, Christopher , Spencer, David , Srinivasan, Shraddha, Tatum, William O. , Ness, Paul Van, Vossler, David G. , Wharen, Robert E. , Yoshor, Daniel , Zimmerman, Richard S. , Skarpaas, Tara L. , Morrell, Martha J. , Noe, Katherine H. , Edwards, Jonathan C. W. , Goldman, Alica M. , Goodman, Robert , Gross, Robert E. , Smith, Michael C. F. , Worrell, Gregory A. , Cole, Andrew J , Fountain, Nathan , Hirsch, Lawrence J , Meador, Kimford J , Jobst, Barbara , Nair, Dileep R , Skidmore, Christopher , Morrell, Martha J

Mayo Clinic

Epilepsia | April 7, 2017 | Volume: 58 | Issue: 6 | Pages: 1005-1014

10.1111/epi.13739 | PMID 28387951 Get It

SummaryObjectiveEvaluate the seizure‐reduction response and safety of brain‐responsive stimulation in adults with medically intractable partial‐onset seizures of neocortical origin.MethodsPatients with partial seizures of neocortical origin were identified from prospective clinical trials of a brain‐responsive neurostimulator (RNS System, NeuroPace). The seizure reduction over years 2–6 postimplantation was calculated by assessing the seizure frequency compared to a preimplantation baseline. Safety was assessed based on reported adverse events. Additional analyses considered safety and seizure reduction according to lobe and functional area (e.g., eloquent cortex) of seizure onset.ResultsThere were 126 patients with seizures of neocortical onset. The average follow‐up was 6.1 implant years. The median percent seizure reduction was 70% in patients with frontal and parietal seizure onsets, 58% in those with temporal neocortical onsets, and 51% in those with multilobar onsets (last observation carried forward [LOCF] analysis). Twenty‐six percent of patients experienced at least one seizure‐free period of 6 months or longer and 14% experienced at least one seizure‐free period of 1 year or longer. Patients with lesions on magnetic resonance imaging (MRI; 77% reduction, LOCF) and those with normal MRI findings (45% reduction, LOCF) benefitted, although the treatment response was more robust in patients with an MRI lesion (p = 0.02, generalized estimating equation [GEE]). There were no differences in the seizure reduction in patients with and without prior epilepsy surgery or vagus nerve stimulation. Stimulation parameters used for treatment did not cause acute or chronic neurologic deficits, even in eloquent cortical areas. The rates of infection (0.017 per patient implant year) and perioperative hemorrhage (0.8%) were not greater than with other neurostimulation devices.SignificanceBrain‐responsive stimulation represents a safe and effective treatment option for patients with medically intractable epilepsy, including adults with seizures of neocortical onset, and those with onsets from eloquent cortex.